TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20497950

Group type: EXPERIMENTAL
Intervention: 4% ethanol beer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alcohol-free beer
Number of subjects: 12
Study: 18318696

Group type: EXPERIMENTAL
Intervention: Pepsi Cola added to 0.75 mg x kg(‐1) midazolam
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 10% sodium citrate added to 0.75 mg x kg(‐1) midazolam
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pomegranate juice added to 0.75 mg x kg(‐1) midazolam
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Grapefruit juice added to 0.75 mg x kg(‐1) midazolam
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.75 mg x kg(‐1) midazolam without any additive
Number of subjects: 75
Study: 16046950

Group type: EXPERIMENTAL
Intervention: Wrist blood pressure oscillometer
Number of subjects: 2493

Group type: COMPARATOR
Intervention: Mercury sphygmomanometer
Number of subjects: 2493
Study: 12217670

Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional discectomy
Number of subjects: 27
Study: 9527730

Group type: EXPERIMENTAL
Intervention: Propofol sedation (5 mg kg(‐1) h(‐1) initially, titrated to 2.4+/‐0.7 mg kg(‐1) h(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: i.v. saline (control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (i.v. saline)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 10
Study: 7629525

Group type: EXPERIMENTAL
Intervention: Aspirin (30 or 283 mg)
Number of subjects: 2437
Study: 2799022

Group type: EXPERIMENTAL
Intervention: Tiapride (7.5 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dihydrobenzoperidol plus fentanyl
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diazepam plus haloperidol
Number of subjects: 16
Study: 62946

Group type: EXPERIMENTAL
Intervention: Rifampicin plus isoniazid for nine months, supplemented by ethambutol (25 mg/kg for the first two months)
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Rifampicin plus isoniazid for twelve months, supplemented by ethambutol
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Rifampicin plus isoniazid for six months, supplemented by ethambutol
Number of subjects: 696

Group type: COMPARATOR
Intervention: Streptomycin (adverse effects noted)
Number of subjects: 696
Study: 30796855

Group type: EXPERIMENTAL
Intervention: Exogenous lactase preparation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-lactose diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 40
Study: 28489856

Group type: EXPERIMENTAL
Intervention: Continue ART
Number of subjects: 1652

Group type: COMPARATOR
Intervention: Discontinue ART
Number of subjects: 1652
Study: 25582225

Group type: EXPERIMENTAL
Intervention: Gene expression network methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene set enrichment analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma biomarker myeloperoxidase (MPO)
Number of subjects: 0
Study: 22246615

Group type: COMPARATOR
Intervention: Informational booklet
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Booklet + face‐to‐face parent training sessions
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Booklet + web‐based parent training sessions
Number of subjects: 99
Study: 22145355

Group type: EXPERIMENTAL
Intervention: 2% acid‐soluble chitosan solution (200‐250 kDa molecular weight)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (practically healthy women)
Number of subjects: 76
Study: 19628651

Group type: EXPERIMENTAL
Intervention: Co-administration of acylated ghrelin (AG) 100 microg and unacylated ghrelin (UAG) 100 microg (Comb)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Unacylated ghrelin (UAG) 200 microg
Number of subjects: 8
Study: 16358341

Group type: EXPERIMENTAL
Intervention: Maximal expiratory pressures (P(Emax))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Forced vital capacity (FVC)
Number of subjects: 24
Study: 15546290

Group type: EXPERIMENTAL
Intervention: Everolimus-coated stents
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bare metal stents (Control)
Number of subjects: 42
Study: 27272073

Group type: EXPERIMENTAL
Intervention: Topical agent designed to reduce P. acnes biofilm
Number of subjects: 0
Study: 10822123

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (0.625 mg/day oral conjugated estrogen)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy with continuous low-dose progestin (2.5 mg oral medroxyprogesterone acetate/day)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 8628357

Group type: EXPERIMENTAL
Intervention: Nadolol plus isosorbide mononitrate
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 86
Study: 2010785

Group type: EXPERIMENTAL
Intervention: Responsiveness index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two different instruments
Number of subjects: 0
Study: 6405431

Group type: EXPERIMENTAL
Intervention: Alcoholic beverage (0.50 g/kg body weight)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonalcoholic beverage
Number of subjects: 48
Study: 30130407

Group type: EXPERIMENTAL
Intervention: AuNR@SiO2
Number of subjects: 4

Group type: COMPARATOR
Intervention: AuNR@CTAB, AuNR@PSS, AuNR@mPEG
Number of subjects: 4
Study: 27173369

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (5 mg/kg)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 24477761

Group type: EXPERIMENTAL
Intervention: Full DoF reaching movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tangential hand velocity
Number of subjects: 0
Study: 23155023

Group type: EXPERIMENTAL
Intervention: SBM-based diet with GGMO-AX (4%)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: SPI-based diet with cellulose (4%)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: SBM-based diet
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Infected chicks (SBM-fed)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Infection status
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cecal tonsil cytokine expression
Number of subjects: 200
Study: 20236248

Group type: EXPERIMENTAL
Intervention: ADX10059 125 mg b.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ADX10059 250 mg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17261559

Group type: EXPERIMENTAL
Intervention: Eccentric training (various protocols including drop squats, slow eccentric movement, squatting on decline board or level ground, etc.) for 12 weeks, twice daily.
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Eccentric training with decline board and some level of discomfort.
Number of subjects: 162
Study: 15855570

Group type: EXPERIMENTAL
Intervention: INH (6 mg)
Number of subjects: 17
Study: 11997197

Group type: EXPERIMENTAL
Intervention: Avinza 30 mg once daily
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: MS Contin 15 mg twice daily
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 295
Study: 9803694

Group type: EXPERIMENTAL
Intervention: Counseling plus vouchers for cocaine-free urine samples (Voucher Schedule 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Voucher Schedule 2 (high initial voucher values, increasing requirements)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Voucher Schedule 1 (low initial voucher values, increasing requirements)
Number of subjects: 90
Study: 14588450

Group type: EXPERIMENTAL
Intervention: Malingering group (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 60
Study: 2749302

Group type: EXPERIMENTAL
Intervention: Self-care educational session
Number of subjects: 572

Group type: COMPARATOR
Intervention: No self-care educational session (Control)
Number of subjects: 572
Study: 30107283

Group type: EXPERIMENTAL
Intervention: MEDI3902 (250 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: MEDI3902 (750 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: MEDI3902 (1500 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: MEDI3902 (3000 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 29943364

Group type: EXPERIMENTAL
Intervention: Aspirin treatment (100 mg/day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 111
Study: 26763226

Group type: EXPERIMENTAL
Intervention: Complete pulmonary vein isolation (PVI) (group B)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Incomplete pulmonary vein isolation (PVI) (group A)
Number of subjects: 233
Study: 24587780

Group type: EXPERIMENTAL
Intervention: Photon radiotherapy (70 Gy)
Number of subjects: 27
Study: 22467247

Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation (needle inserted at TE5 point, gentle tapping for 90 s)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 55
Study: 19680082

Group type: EXPERIMENTAL
Intervention: Simulation training (SIM)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No simulation training (CON)
Number of subjects: 33
Study: 17005222

Group type: EXPERIMENTAL
Intervention: Coartem
Number of subjects: 500

Group type: COMPARATOR
Intervention: AQ+SP
Number of subjects: 500
Study: 16194047

Group type: EXPERIMENTAL
Intervention: Liv-52 for 6 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 36
Study: 11906367

Group type: EXPERIMENTAL
Intervention: cetirizine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: loratadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ebastine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: fexofenadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: mizolastine
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 10479835

Group type: EXPERIMENTAL
Intervention: 1 microgram/kg remifentanil (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg remifentanil (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg remifentanil (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (All groups)
Number of subjects: 60
Study: 7710545

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 260

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 260
Study: 1936422

Group type: EXPERIMENTAL
Intervention: Omnipaque 350 (75.49% iohexol, 350 mgI ml‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Angioconray (80% sodium iothalamate, 480 mgI ml‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Omnipaque 350
Number of subjects: 80

Group type: COMPARATOR
Intervention: Angioconray
Number of subjects: 80
Study: 7147192

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 26
Study: 31978438

Group type: EXPERIMENTAL
Intervention: Greater Rochester LARC Initiative
Number of subjects: 100

Group type: COMPARATOR
Intervention: New York State
Number of subjects: 100

Group type: COMPARATOR
Intervention: New York City
Number of subjects: 100

Group type: COMPARATOR
Intervention: United States overall
Number of subjects: 100
Study: 30457920

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 28585735

Group type: EXPERIMENTAL
Intervention: 1000 mg green tea extract, two capsules/day
Number of subjects: 68

Group type: COMPARATOR
Intervention: 1000 mg starch, two capsules/day
Number of subjects: 68
Study: 24993562

Group type: COMPARATOR
Intervention: SINGLE (once daily training)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: REPEATED (twice every second day training)
Number of subjects: 20
Study: 23434504

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU 4 times per day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 21372694

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (5/160 mg) in the morning
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (5/160 mg) in the evening
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (10/160 mg) after uptitration if needed
Number of subjects: 463

Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 463
Study: 19109514

Group type: EXPERIMENTAL
Intervention: Asymptomatic precachexia (class 1)
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Symptomatic cachexia (class 4)
Number of subjects: 1307
Study: 17970056

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study: 15380292

Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tiagabine (8 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cocaine (150 mg)
Number of subjects: 10
Study: 11340346

Group type: EXPERIMENTAL
Intervention: Nephrotic group
Number of subjects: 33
Study: 9701103

Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10-40 mg/d), possibly combined with enalapril maleate (5-20 mg/d) and/or hydrochlorothiazide (12.5-25 mg/d)
Number of subjects: 4695
Study: 8149523

Group type: EXPERIMENTAL
Intervention: Plasma endothelin determination on day 3 after myocardial infarction
Number of subjects: 142

Group type: COMPARATOR
Intervention: Clinical and biochemical variables (age, previous treatment for systemic hypertension, presence of clinical heart failure, plasma atrial natriuretic factor levels)
Number of subjects: 142
Study: 3141641

Group type: EXPERIMENTAL
Intervention: Guidewire change every 3 days
Number of subjects: 126

Group type: COMPARATOR
Intervention: Guidewire changes for mechanical or septic complications only
Number of subjects: 126
Study: 29622155

Group type: EXPERIMENTAL
Intervention: Heart Failure (HF)
Number of subjects: 28341

Group type: EXPERIMENTAL
Intervention: Landmark method analysis at 70 years of age
Number of subjects: 28341
Study: 26427002

Group type: EXPERIMENTAL
Intervention: In-class didactic teaching (group 1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Self-directed teaching (group 2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall accuracy
Number of subjects: 18
Study: 25236478

Group type: EXPERIMENTAL
Intervention: Multi-component physical activity intervention (PA during academic lessons, PA during recess, PA homework, cycling campaign) for 5 months.
Number of subjects: 759
Study: 22099051

Group type: EXPERIMENTAL
Intervention: RHES plus radiotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 50
Study: 20649631

Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Extended Intervention (EI)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI) and Extended Intervention (EI)
Number of subjects: 98
Study: 18793245

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20,000 or 40,000 IU per week)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 16351387

Group type: EXPERIMENTAL
Intervention: Daily Abstinence Self-Efficacy (ASE)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Positive Smoking Outcome Expectancies (POEs)
Number of subjects: 305
Study: 12009390

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 12

Group type: COMPARATOR
Intervention: Minimal acupuncture (placebo)
Number of subjects: 12
Study: 10736883

Group type: EXPERIMENTAL
Intervention: Educational intervention (invitation to consult with a trained practice nurse)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 270
Study: 7601995

Group type: EXPERIMENTAL
Intervention: Community-based education/support programme
Number of subjects: 0
Study: 2190851

Group type: EXPERIMENTAL
Intervention: Pentasa (1.5 g daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (dummy tablet)
Number of subjects: 40
Study: 7438324

Group type: EXPERIMENTAL
Intervention: Cystectomy plus preoperative irradiation (6.5 Gy X 2F/1 week) with misonidazole (3 g/m2, two doses, orally)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cystectomy plus preoperative irradiation (4.0 Gy X 5F) with misonidazole (2 g/m2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Split course (SC) protracted regime with misonidazole (0.5 g/m2 daily doses, total dose 14 g/m2 over 61 days)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HF) with misonidazole (2 g/m2 daily doses, total dose 14 g/m2 over 35 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cystectomy alone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cystectomy plus preoperative irradiation (6.5 Gy X 2F/1 week) without misonidazole
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cystectomy plus preoperative irradiation (4.0 Gy X 5F) without misonidazole
Number of subjects: 28
Study: 31251892

Group type: EXPERIMENTAL
Intervention: RPE-guided aerobic training (n=11; 16 weeks, 20 min, twice weekly at RPE 3-6)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Active control (n=8; access to exercise equipment without specific advice)
Number of subjects: 19
Study: 31152658

Group type: EXPERIMENTAL
Intervention: mMPC (mineral modified milk protein concentrate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MPC (milk protein concentrate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CAS (calcium caseinate)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: mMPC
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups (mMPC, MPC, CAS)
Number of subjects: 30
Study: 27577177

Group type: EXPERIMENTAL
Intervention: Pomegranate extract (POMx), 2 capsules of 250 mg per day for 8 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cellulose (control), 2 capsules of 250 mg per day for 8 weeks
Number of subjects: 55
Study: 26176930

Group type: EXPERIMENTAL
Intervention: active tDCS
Number of subjects: 240

Group type: COMPARATOR
Intervention: sham tDCS/escitalopram 20 mg/day
Number of subjects: 240

Group type: COMPARATOR
Intervention: sham tDCS/placebo pill
Number of subjects: 240
Study: 22717170

Group type: EXPERIMENTAL
Intervention: l‐tryptophan (2.8g/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study: 22358274

Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation) applied for 30 minutes, three times a day, along with analgesic therapy and physiotherapy.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group received more physiotherapy analgesic therapy without TENS.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TENS group for inspiratory muscle strength.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group for inspiratory muscle strength.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TENS group for expiratory muscle strength.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group for expiratory muscle strength.
Number of subjects: 20
Study: 18327706

Group type: EXPERIMENTAL
Intervention: Aprepitant-based regimen (day 1: aprepitant 125 mg, ondansetron 8 mg, dexamethasone 12 mg before chemotherapy; ondansetron 8 mg 8 h later; days 2-3: aprepitant 80 mg qd)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard regimen (day 1: ondansetron 8 mg and dexamethasone 20 mg before chemotherapy; ondansetron 8 mg 8 h later; days 2-3: ondansetron 8 mg bid)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Aprepitant-based regimen
Number of subjects: 124
Study: 17347792

Group type: EXPERIMENTAL
Intervention: Full-length autologous slings (Group A)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Modified 'sling-on-a-string' technique (Group B)
Number of subjects: 165
Study: 15033400

Group type: EXPERIMENTAL
Intervention: Yasmin (30 microg ethinylestradiol + 3 mg drospirenone)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Marvelon (30 microg ethinylestradiol + 150 microg desogestrel)
Number of subjects: 50
Study: 11793859

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA) at an initial dosage of 5 mg.kg‐1.d‐1, gradually tailed off over three months and maintained at 2 mg.kg‐1.d‐1 for 12 months.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Captopril (CAP) at a dosage of 37.5 mg/day.
Number of subjects: 30
Study: 9547527

Group type: EXPERIMENTAL
Intervention: Child Find screening and assessment (CF group)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Nonreferred children (Comparison group)
Number of subjects: 128
Study: 8063043

Group type: EXPERIMENTAL
Intervention: 3 mg of the ACTH4-9 analogue ORG 2766 every 24 h
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 3281838

Group type: EXPERIMENTAL
Intervention: Sodium meglumine ioxaglate (320 or 306 mg I/ml)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Meglumine diatrizoate (306 mg I/ml)
Number of subjects: 209
Study: 29241105

Group type: COMPARATOR
Intervention: Computer-generated individualized feedback letters
Number of subjects: 961

Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 961
Study: 28760121

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA) 10 mg/kg 20 minutes preoperatively and 3 hours after first dose
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intra-articular tranexamic acid (TA) 3 g locally into surgical site
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no TA)
Number of subjects: 90
Study: 25917434

Group type: EXPERIMENTAL
Intervention: air-Q
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ambu Aura-i
Number of subjects: 64
Study: 23442351

Group type: EXPERIMENTAL
Intervention: Prolongation of life (POL) format for risk communication
Number of subjects: 328

Group type: COMPARATOR
Intervention: Absolute risk reduction (ARR) format for risk communication
Number of subjects: 328